Rose McNulty

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Findings reveal that alternative polyadenylation regulates SASP factors and may fuel age-related pulmonary fibrosis.

Mepolizumab showed significant real-world improvements in asthma outcomes, reducing exacerbations and corticosteroid use in severe eosinophilic asthma.

John Byrnes of Banner|Aetna emphasizes collaboration and data-driven strategies to enhance care quality, access, and affordability in health care.

US foreign aid budget cuts and freezes may potentially increase those affected by tuberculosis in USAID-dependent countries, resulting in millions of lives lost.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

Olivo Adriana, NP, highlights the importance of survivorship care and how providers are utilizing available tools to the best of their ability.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

Adults with food insecurity report higher rates of long COVID and lower recovery, with Supplemental Nutrition Assistance Program (SNAP) participation and employment status affecting these associations.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

Cilta-cel demonstrates superior efficacy and durability in treating high-risk myeloma, balancing effectiveness with safety concerns for patients.

The use of cemiplimab with chemotherapy showed durable improvements in survival outcomes for non-small cell lung cancer (NSCLC) after 5 years.

Pulse of the Purchaser 2025 survey results showed the use of transparent PBMs more than doubled in just 1 year, from 12% to 31%.

Byoung Chul Cho, MD, PhD, of the Yonsei University College of Medicine, discussed outcomes in the COCOON trial of an enhanced dermatologic regimen with amivantamab-lazertinib treatment.

Novel models incorporating tumor deposits outperform tumor TNM in predicting outcomes.

Efren Flores, MD, of Harvard Medical School and Massachusetts General Hospital, discussed the findings of a subanalysis of the Screen ASSIST tobacco cessation clinical trial.

Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).

The chronic spontaneous urticaria treatment landscape has shifted in recent years, with expanding treatment options for patients with refractory disease.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed the latest advancements in value-based multiple myeloma care, including minimal residual disease strategies and innovative targeted therapies.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

Emma Guttman-Yassky, MD, PhD, discusses promising hair regrowth results for alopecia areata treatments, emphasizing safety and rapid efficacy.

Research highlights a strong link between Epstein-Barr virus and multiple sclerosis (MS), suggesting new therapeutic strategies targeting the virus for MS treatment.

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.

Polyethylene terephthalate microplastics are the most common microplastics encountered in daily life, and there are several reasons why they may play a role in lung diseases like idiopathic pulmonary fibrosis.

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.

Long-term follow-up data on the use of BCMA-directed RNA chimeric antigen receptor T-cell therapy (CAR T) for refractory generalized myasthenia gravis show patient outcomes at 2, 3, 6, 9, and 12 months.

Weekly mobile messages improved blood sugar, blood pressure, and heart health risk management in patients with type 2 diabetes (T2D), a study finds.

Patients with small cell lung cancer (SCLC) experienced better responses to immune checkpoint inhibitors if they had higher levels of NOTCH1 expression in a recent study.